| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
The Vollum Institute (A.A.B.), Oregon Health Sciences University, Portland, Oregon 97201, Clinical Endocrinology Branch (D.L.), NIDDK, National Institutes of Health, Bethesda, Maryland 20892-1758
Address all correspondence and requests for reprints to: Derek LeRoith, National Instututes of Health 3, NIH MSC 1758, Building 10, Room 8D12, 10 Center Drive, Bethesda, Maryland 20892-1758. E-mail: derek{at}helix.nih.gov
 |
Abstract |
|---|
 Top Abstract IntroductionReferences |
|---|
The insulin-like growth factors (IGF-I and IGF-II) and the IGF-I receptor are critically important for normal growth and development of the organism. Gene-deletion of these elements has demonstrated that IGF-I is important for both prenatal and postnatal development, whereas IGF-II is important during prenatal stages only. The IGF-I receptor gene-deleted mouse dies at birth apparently as a result of poor muscular development. Utilizing the conditional gene-deletion approach, we have demonstrated that mice lacking the liver IGF-I gene have an approximately 80% reduction in circulating total IGF-I levels. Despite this marked reduction, postnatal growth and development was normal, suggesting that liver IGF-I is not essential for this function. Local tissue IGF-I production was unaffected and may compensate for the lack of the liver IGF-I. Further studies are ongoing to establish the role of the endocrine vs. the autocrine/paracrine IGF-I.
|
Introduction |
|---|
|
TopAbstractIntroductionReferences |
|---|
The IGF family of ligands and receptors is homologous to the
insulin/insulin receptor (IR) combination, suggesting a common
evolutionary heritage. The IGF-IR is activated by IGF-I and IGF-II, and
like the IR has an 
2ß2
heterotetrameric structure (1). The receptors are coupled
to several common intracellular second messenger pathways, for example
the tyrosine kinase of both receptors target the insulin-receptor
substrate (IRS) family of docking proteins (1). However,
there is increasing evidence for receptor specificity in second
messenger systems. Still, one of the questions that remains to be
definitively answered is how such similar receptors possess distinct
biological actions. The IGF2R (also known as the mannose-6 phosphate
receptor) is structurally distinct, and binds IGF-II but not IGF-I with
high affinity. The IGF2R appears to lack any of the major intracellular
domains associated with signal transduction. Its primary function
appears to be inhibition of the actions of IGF-II in utero,
controlling interstitial IGF-II concentrations by endocytosis and
targeting to lysozomes for degradation (5).
The first papers from Argiris Efstratiadis and colleagues at Columbia University (New York, NY) describing the phenotype of igf1-/-, igf2-/-,igf1r-/-, igf2r-/-, and the various crosses were published almost a decade ago (3, 4, 6, 7). These papers revealed for the first time the essential role of the IGFs in promoting growth in and ex utero. While this is perhaps not surprising given their ubiquitous nature, it is easy to forget today that these original studies yielded some surprising insights into the role of IGF-I, IGF-II, IGF-IR, and the IGF2R. Mice lacking either the igf1 or igf2 genes exhibited intrauterine growth retardation, with weights approximately 60% that of wild-type littermates. Mice lacking a functional igf1r gene were born weighing only 45% of normal and died soon after birth from respiratory failure. While exhibiting intrauterine growth retardation, the postnatal growth in igf2 null mice was found to be essentially normal. In distinct contrast, igf2r null mice exhibit a fetal overgrowth syndrome that is lethal. The lethal phenotype associated with the inactivation of the igf2r gene could be partially rescued by crossing onto a igf2-/- background, indicating that excess IGF-II is detrimental to fetal development and that the IGF2R functions to prevent this from occurring (5).
The studies of DeChiara and colleagues also made a seminal contribution to our understanding of the parental imprinting of genes (7). The discovery of the reciprocal parental imprinting of the igf2 and igf2r genes was an extremely important insight, both in terms of understanding the conflicting paternal and maternal priorities for controlling fetal growth and for discovering an important mechanism underlying carcinogenesis (8, 9). The information gathered from the crosses of the respective lines was also important, giving critical insights into how the components of the system interact.
The results derived from experiments where the various knockouts were crossed also provided genetic evidence of a role for a further receptor, recently identified as the IR, in mediating IGF-II’s effects on fetal growth. The dwarf phenotype of igf1/igf2 double knockouts was more severe than that associated with either single deletion (i.e. igf1-/- or igf2-/-) or the igf1r knockout, resulting in pups only 30% normal weight. The phenotype of the igf1/igf1r double knockout appeared identical to that of the igf1r knockout, suggesting that IGF-I was acting exclusively through the IGF-IR. In contrast, the igf2/igf1r double knockout had a growth retardation more severe than the igf1r knockout, suggesting that IGF-II acts through another receptor in addition to the IGF-IR. The unknown receptor mediating some of the effect of IGF-II on fetal growth was recently identified by genetic methods as being the IR (10). An independent study has revealed the existence of a splice-variant of the IR which has a high affinity for IGF-II and is highly expressed in fetal and neoplastic tissues (11). Thus the IGFs act to stimulate fetal growth through both the IGF-IR and the IR, whereas the IGF-II/mannose-6-phosphate receptor appears to inhibit the effects of IGF-II on fetal growth.
Despite the obvious success of these experiments, questions remain to be answered about the role of the IGF system in the more specialized tissues of the adult. The original knockout studies painted a picture of the somatotropic axis using a necessarily broad brush. However, the fragility of the offspring meant that investigating the organ-specific functions of the IGF system in the adult was extremely difficult. For example, what role do the IGFs have in regulating ovarian function? Is the regulation of adrenal steroidogenesis by IGF physiologically relevant? Does the IGF-IR have insulin-like functions in muscle, and what is the function of liver IGF-I? Due to the severity of the growth retardation, not to mention significant pup mortality, answering these questions is difficult, if not impossible, using the igf1 and igf1r knockouts first described.
The discovery by Brian Sauer that the Cre recombinase of bacteriophage P1 could be used to rearrange the eukaryote genome suggested a mechanism that would remove the restriction against introducing a mutation specifically into somatic cells (12). The first report of the successful application of this approach, inactivating the DNA polymerase ß gene in T cells, was published in 1994 (13). Before this, gene targeting by necessity meant knocking out a gene in stem cells, and introducing this null allele into the germline. The study of genes in mature mice was only possible if these genes did not also possess a significant function during embryonic and fetal growth. Two lines of mice are required for the Cre-loxP approach to work. In one line, the targeted allele is flanked by two loxP sequences, which target the flanked region for excision by the Cre recombinase. In another line, the expression of Cre is controlled by a cell-specific promoter. Crossing the two lines of mice leads to an animal lacking the gene only in cells that express Cre, while leaving the gene functional in all other tissues. The advantages of such a system are obvious: the function of genes necessary for fetal development can be preserved, allowing the function(s) of the gene to be examined during adulthood.
Mice in which exons of the igf1 or igf1r genes have been flanked by loxP sites have been generated (14, 15, 16). One of the two igf1r/lox mouse lines has been reported as a model of partial IGF-IR deficiency, in that the neomycin resistance gene interferes with the processing of the nascent IGF-IR transcript (14). However, so far there has been no information reported regarding tissue-specific knockouts using either line. Of the three lines generated, only the igf1 gene has been successfully targeted in a truly tissue-specific manner (17). To control the function of the igf1 gene, loxP sites were inserted by homologous recombination 5' and 3' to exon 4 (16). Mice homozygous for the loxP-flanked allele displayed a minor (less than 10%) reduction in size, but were otherwise normal. Analysis of the offspring of mice hemizygous for the loxP-flanked allele and expressing Cre under the control of the EIIa promoter proved that the loxP sites were functional. The EIIa promoter used to drive Cre expression in this study is active during early embryogenesis, and perhaps during preimplantation development. The use of the EIIa promoter resulted in offspring with variable levels of recombination of the loxP-flanked allele, with a significant correlation observed between the degree of recombination and the severity of growth retardation. In the most severe cases of recombination (90–100%), a phenotype similar to that reported for the classical igf1 knockout was observed, with a 30% reduction in body weight and perinatal mortality.
Having established that the igf1/lox allele was functional, we next set out to answer perhaps one of the most intriguing and long-standing of questions concerning the somatotropic axis: what is the function of IGF-I produced in the liver? Whether the liver is the primary source of endocrine IGF-I had been in question for nearly two decades, since the widespread expression of the IGFs was first recognized. At the time, the liver was believed to the primary source of IGF-I in the circulation. IGF-I mRNA levels in the liver are expressed at a level 10- to 100-fold greater than in the majority of other tissues, with the exception being adipose tissue. Hepatic IGF-I mRNA expression increases dramatically in the liver postnatally, coincident with a dramatic increase in serum IGF-I levels; thus, the function of hepatic derived IGF-I appears to become more important with age. The coincidence of the increase in serum IGF-I and hepatic IGF-I mRNA with the onset of GH-dependent growth is provocative, suggesting the liver-derived IGF-I might also play a role in the "GH-dependent" phase of growth. Liver IGF-I mRNA expression also exhibits by far the greatest response to manipulation of GH levels. Finally, hepatocytes do not express the IGF-IR; thus, IGF-I produced by these cells appears destined for export and not for local action. Taken together, the data suggested that circulating IGF-I played an integral role in the actions of GH.
By crossing the igf1/lox mice with a transgenic line expressing Cre under the control of the albumin promoter (Alb-Cre), we were able to generate mice with essentially no IGF-I mRNA expression in the liver (17). Surprisingly, there appeared to be little effect on growth postnatally, despite a marked (75%) reduction in the concentration of total IGF-I in serum. This study, along with the results of further experiments on these mice, have confirmed that hepatocytes are indeed the primary source of IGF-I in the circulation. In a more recent study, it was shown that while GH treatment of female hepatocyte-specific igf1-/- mice increased growth rate and IGF-I mRNA expression in brown and white fat; this occurred without significant changes in serum IGF-I levels (18). Both observations are consistent with the liver representing the primary source of serum IGF-I, and that the increase in IGF-I in the circulation following GH treatment is most likely hepatic in origin. The data derived from the experiments described in Yakar et al. were confirmed independently by a group using the same lox-igf1 line of mice in conjunction with a line of mice expressing Cre under the control of an interferon-inducible promoter (Mx-Cre) (19). Treatment of the lox-igf1. Mx-Cre mice with interferon causes almost complete recombination in liver, and partial recombination in spleen, leading to a marked reduction in serum IGF-I without affecting growth rate.
Interestingly, the phenotype of the acid-labile subunit (ALS) knockout mice bears a striking resemblance to that of the hepatic-specific igf1 knockouts (20). ALS mRNA expression is restricted to hepatocytes (21). By forming a ternary complex with an IGF and either IGFBP-3 or IGFBP-5, ALS stabilizes and thereby prolongs the half life of IGF in the circulatory system. Targeted deletion of the murine ALS gene was associated with a 60% reduction in circulating IGF-I levels, and an even more dramatic 90% reduction in IGFBP-3 levels. Yet despite the reduction in serum IGF-I, as observed in the studies using hepatic-specific deletion of the igf1 gene, there was not a major effect on growth.
While answering one question (i.e. increasing IGF-I in the circulation is not necessary for GH-dependent growth), the initial results of these studies did not really provide a firm answer as to what the function of circulating IGF-I is. One observation suggests that circulating IGF-I has an important feedback function within the somatotropic axis: serum GH levels are increased in both models of hepatic IGF-I deficiency, consistent with a reduction in the inhibitory effect of circulating IGF-I on GH release from the somatotroph. This result, while not novel in that the feedback effect of IGF-I on pituitary GH release has been known of for almost two decades, might be an important clue as to what the primary function of liver-derived IGF-I is. The increase in serum GH might also explain the lack of growth retardation. The expression of IGF-I mRNA in nonhepatic tissues was normal, as was the concentration of "free" IGF-I in the circulation. Thus, perhaps by a combination of increased GH and by the normal expression of IGF-I mRNA in extra-hepatic tissues, growth is not affected in the absence of hepatic-derived IGF-I.
One question remained, however, and that is whether a persistent mild hypersomatotropism would ultimately have pathological effects in the adult. In this respect, it is interesting to note that there is a deficit associated with the loss of hepatic-derived IGF-I (22). Mice in which the hepatocyte igf1 allele has been deleted develop insulin resistance. This effect is tissue-specific: IR and IRS-1 phosphorylation in response to insulin treatment is markedly inhibited in muscle but not in liver. Whether the insulin-insensitivity is due to the chronic elevation of GH, or perhaps reflects a direct "sensitizing" effect of IGF-I remains to be determined. In any event, this data clearly shows that while not necessary for growth per se a possible physiological role for hepatic-derived IGF-I is to act as a restraint GH secretion and regulate glucose homeostasis, perhaps at a postreceptor level. It will be interesting to determine whether there are other pathological consequences associated with chronic hypersomatotropism and hyperinsulinemia (e.g. hypertension, atherosclerosis, glomerular sclerosis, obesity).
There are still uncertainties to the model of endocrine IGF-I function presented in this text. For example, the ALS knockout mouse does not exhibit a defect in glucose homeostasis (20). This discrepancy might be due to the different mouse strains employed, Ueki et al. (20) crossed the chimeric mice with BALB/c females, whereas Yakar et al. (22) used the C57BL/6J strain. It is also important to note that the results of these studies do not rule out a role of circulating IGF-I in mediating the effects of GH on somatic growth, since the hypersomatotropism itself may mask any effects. "Free" IGF-I levels in the circulation of hepatic igf1-/- mice are also normal, suggesting that there has not been a reduction in biologically active IGF-I. If this is indeed the case, why the increase in serum GH? Clearly, much work remains to be done characterizing the deficits associated with the loss of hepatocyte IGF-I mRNA expression.
The overexpression of IGF-I and IGF-II using cell-type specific promoters has also provided some valuable insights and remains a valid method for investigating IGF function. This approach has been successfully used to examine cell-type specific functions of IGF in vivo. For example, overexpression of IGF-I in osteoblasts leads to an increase rate of bone formation and a significant increase in bone mineral density (23). Surprisingly, the increase in bone density associated with IGF-I expression in osteoblasts occurs without changes in the number of osteoblasts or osteoclasts.
Loss of function experiments, in which a transgene controlled by a cell-type specific promoter expresses a dominant negative protein, have also been successfully used to examine the role of the IR in liver and muscle in glucose homeostasis by using kinase-deficient receptors (24). This laboratory has successfully targeted the expression of a dominant negative IGF-IR to muscle, using a muscle creatine kinase promoter (25). These mice exhibit a transient postnatal growth retardation, with a reduction in weight in the first 4 to 6 weeks postpartum. Interestingly, these mice also exhibit insulin resistance, perhaps due to the formation of hybrids composed of the wild-type IR and the kinase-deficient IGF-IR. The in vivo approach may ultimately prove to be a valuable adjunct to cell culture studies that have examined the function of the distinct C-terminal regions of the IGF-IR in controlling cell division and migration.
Both the Cre-lox and transgenic approaches can provide important information about the functions of the IGF system. Mice in which the igf1 and the igf1r contain loxP sites flanking important coding regions have been generated and successfully manipulated by crossing with transgenic mice expressing Cre controlled by a variety of promoters. The igf1 gene has been successfully deleted in hepatocytes; future efforts will include the use of muscle-, bone-, neural-, hematopoetic, and adipocyte-specific Cre transgenes. Despite the technical challenges in successfully employing this technology, new insights into the IGF system have never been closer.
Received December 15, 2000.
|
References |
|---|
|
TopAbstractIntroductionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  Z. Wang, R. M. Luque, R. D. Kineman, V. H. Ray, K. T. Christov, D. D. Lantvit, T. Shirai, S. Hedayat, T. G. Unterman, M. C. Bosland, et al. Disruption of Growth Hormone Signaling Retards Prostate Carcinogenesis in the Probasin/TAg Rat Endocrinology, March 1, 2008; 149(3): 1366 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Gahr, R. L. Vallejo, G. M. Weber, B. S. Shepherd, J. T. Silverstein, and C. E. Rexroad III Effects of short-term growth hormone treatment on liver and muscle transcriptomes in rainbow trout (Oncorhynchus mykiss) Physiol Genomics, February 19, 2008; 32(3): 380 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Marzetti, L. Groban, S. E. Wohlgemuth, H. A. Lees, M. Lin, H. Jobe, S. Giovannini, C. Leeuwenburgh, and C. S. Carter Effects of short-term GH supplementation and treadmill exercise training on physical performance and skeletal muscle apoptosis in old rats Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R558 - R567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Alfieri, H. J. Evans-Anderson, and K. E. Yutzey Developmental regulation of the mouse IGF-I exon 1 promoter region by calcineurin activation of NFAT in skeletal muscle Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1887 - C1894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter Small for Gestational Age: Short Stature and Beyond Endocr. Rev., April 1, 2007; 28(2): 219 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Levitsky Defining the Role of IGF-I Therapy for Short Children J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 813 - 814. [Full Text] [PDF]
|
|
|
|
 |
|
 I. El Khattabi, C. Remacle, and B. Reusens The regulation of IGFs and IGFBPs by prolactin in primary culture of fetal rat hepatocytes is influenced by maternal malnutrition Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E835 - E842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liao, R. K. Dearth, S. Zhou, O. L. Britton, A. V. Lee, and J. Xu Liver-Specific Overexpression of the Insulin-like Growth Factor-I Enhances Somatic Growth and Partially Prevents the Effects of Growth Hormone Deficiency Endocrinology, August 1, 2006; 147(8): 3877 - 3888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Miller and D. Yee Type I Insulin-like Growth Factor Receptor as a Therapeutic Target in Cancer Cancer Res., November 15, 2005; 65(22): 10123 - 10127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Gao, P. J. Reiser, C. C. Coss, M. A. Phelps, J. D. Kearbey, D. D. Miller, and J. T. Dalton Selective Androgen Receptor Modulator Treatment Improves Muscle Strength and Body Composition and Prevents Bone Loss in Orchidectomized Rats Endocrinology, November 1, 2005; 146(11): 4887 - 4897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M D Ashworth, J W Ross, D R Stein, D T Allen, L J Spicer, and R D Geisert Endocrine disruption of uterine insulin-like growth factor expression in the pregnant gilt Reproduction, October 1, 2005; 130(4): 545 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Dufresne and R. J. Smith The Adapter Protein GRB10 Is an Endogenous Negative Regulator of Insulin-Like Growth Factor Signaling Endocrinology, October 1, 2005; 146(10): 4399 - 4409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Miquet, A. I. Sotelo, A. Bartke, and D. Turyn Desensitization of the JAK2/STAT5 GH signaling pathway associated with increased CIS protein content in liver of pregnant mice Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E600 - E607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Shaikh, F H Bloomfield, M K Bauer, H H Phua, R S Gilmour, and J E Harding Amniotic IGF-I supplementation of growth-restricted fetal sheep alters IGF-I and IGF receptor type 1 mRNA and protein levels in placental and fetal tissues J. Endocrinol., July 1, 2005; 186(1): 145 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Holsberger, G. M. Buchold, M. C. Leal, S. E. Kiesewetter, D. A. O'Brien, R. A. Hess, L. R. Franca, H. Kiyokawa, and P. S. Cooke Cell-Cycle Inhibitors p27Kip1 and p21Cip1 Regulate Murine Sertoli Cell Proliferation Biol Reprod, June 1, 2005; 72(6): 1429 - 1436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Kong, N. Bodyak, P. Yue, Z. Liu, J. Brown, S. Izumo, and P. M. Kang Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats Physiol Genomics, March 21, 2005; 21(1): 34 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ahlen, J. Wejde, O. Brosjo, A. von Rosen, W.-H. Weng, L. Girnita, O. Larsson, and C. Larsson Insulin-Like Growth Factor Type 1 Receptor Expression Correlates to Good Prognosis in Highly Malignant Soft Tissue Sarcoma Clin. Cancer Res., January 1, 2005; 11(1): 206 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Cao, K. Murao, H. Imachi, X. Yu, H. Dobashi, K. Yoshida, T. Muraoka, N. Kotsuna, S. Nagao, N. C. W. Wong, et al. Insulin-Like Growth Factor-I Regulation of Hepatic Scavenger Receptor Class BI Endocrinology, December 1, 2004; 145(12): 5540 - 5547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rieusset, J. Seydoux, S. I. Anghel, P. Escher, L. Michalik, N. Soon Tan, D. Metzger, P. Chambon, W. Wahli, and B. Desvergne Altered Growth in Male Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) Heterozygous Mice: Involvement of PPAR{gamma} in a Negative Feedback Regulation of Growth Hormone Action Mol. Endocrinol., October 1, 2004; 18(10): 2363 - 2377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Domene, S. V. Bengolea, A. S. Martinez, M. G. Ropelato, P. Pennisi, P. Scaglia, J. J. Heinrich, and H. G. Jasper Deficiency of the Circulating Insulin-like Growth Factor System Associated with Inactivation of the Acid-Labile Subunit Gene N. Engl. J. Med., February 5, 2004; 350(6): 570 - 577. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Edmondson, S. P. Thumiger, G. A. Werther, and C. J. Wraight Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems Endocr. Rev., December 1, 2003; 24(6): 737 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Harper, A. T. Galecki, D. T. Burke, S. L. Pinkosky, and R. A. Miller Quantitative trait loci for insulin-like growth factor I, leptin, thyroxine, and corticosterone in genetically heterogeneous mice Physiol Genomics, September 29, 2003; 15(1): 44 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Georgieva, I. P. Georgiev, E. Ontsouka, H. M. Hammon, M. W. Pfaffl, and J. W. Blum Abundance of message for insulin-like growth factors-I and -II and for receptors for growth hormone, insulin-like growth factors-I and -II, and insulin in the intestine and liver of pre- and full-term calves J Anim Sci, September 1, 2003; 81(9): 2294 - 2300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Lewis, H. Li, Z.-S. Huang, M. S. Biring, B. Cercek, and M. Fournier Influence of varying degrees of malnutrition on IGF-I expression in the rat diaphragm J Appl Physiol, August 1, 2003; 95(2): 555 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fournier, Z.-S. Huang, H. Li, X. Da, B. Cercek, and M. I. Lewis Insulin-like growth factor I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R34 - R43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Boyne, M. Thame, F. I. Bennett, C. Osmond, J. P. Miell, and T. E. Forrester The Relationship among Circulating Insulin-Like Growth Factor (IGF)-I, IGF-Binding Proteins-1 and -2, and Birth Anthropometry: A Prospective Study J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1687 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Fernandez-Celemin, N. Pasko, V. Blomart, and J.-P. Thissen Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha Am J Physiol Endocrinol Metab, December 1, 2002; 283(6): E1279 - E1290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kirsch, E. Koyama, M. Liu, E. E. Golub, and M. Pacifici Syndecan-3 Is a Selective Regulator of Chondrocyte Proliferation J. Biol. Chem., October 25, 2002; 277(44): 42171 - 42177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Valet, G. Tavernier, I. Castan-Laurell, J. S. Saulnier-Blache, and D. Langin Understanding adipose tissue development from transgenic animal models J. Lipid Res., June 1, 2002; 43(6): 835 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Maures, S. J. Chan, B. Xu, H. Sun, J. Ding, and C. Duan Structural, Biochemical, and Expression Analysis of Two Distinct Insulin-Like Growth Factor I Receptors and Their Ligands in Zebrafish Endocrinology, May 1, 2002; 143(5): 1858 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Richards, S. C. Sharma, A. E. Falender, and Y. H. Lo Expression of FKHR, FKHRL1, and AFX Genes in the Rodent Ovary: Evidence for Regulation by IGF-I, Estrogen, and the Gonadotropins Mol. Endocrinol., March 1, 2002; 16(3): 580 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Frank Minireview: Receptor Dimerization in GH and Erythropoietin Action--It Takes Two to Tango, But How? Endocrinology, January 1, 2002; 143(1): 2 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Baxter, S. Meka, and S. M. Firth Molecular Distribution of IGF Binding Protein-5 in Human Serum J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 271 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Smith, E. L. Spurrell, J. Coakley, C. J. Hinds, R. J. M. Ross, A. R. Krainer, and S. L. Chew An Exonic Splicing Enhancer in Human IGF-I Pre-mRNA Mediates Recognition of Alternative Exon 5 by the Serine-Arginine Protein Splicing Factor-2/ Alternative Splicing Factor Endocrinology, January 1, 2002; 143(1): 146 - 154. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
